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Prothrombin fragment 1+2 is excreted in urine (uF1+2) as a result of in vivo thrombin generation and can be a marker of
coagulation status after an operative procedure. This study compared uF1+2 levels in patients with symptomatic and non-
symptomatic venous thromboembolism (VTE) after total knee replacement (TKR) and in event-free sex- and age-matched
controls. Signiﬁcantly higher median uF1+2 levels were seen in the VTE patients on days 1, 3, and the day of venography (mostly
day 7) after TKR compared with controls. The uF1+2 levels tended to be high in some patients with symptomatic VTE; however,
the discriminatory eﬃcacy of the test could not be evaluated. In conclusion, this study showed that patients with VTE tend to have
signiﬁcantly higher uF1+2 levels compared with patients without events between days 1 and 7 after TKR surgery. Measurement of
uF1+2 could provide a simple, non-invasive clinical test to identify patients at risk of VTE.
1.Introduction
Venous thromboembolism (VTE) is a common consequence
oforthopaedicsurgeryandoccursmorefrequentlyaftertotal
knee replacement (TKR) than after total hip replacement
(THR) [1]. Anticoagulation therapy is recommended in
the perioperative period, although the optimal duration of
treatment and the optimal timing of the ﬁrst dose remain
unresolved [1]. Patients at high risk of VTE will beneﬁt from
appropriatethromboprophylaxisafterhospitaldischarge[1].
Therefore, a non-invasive clinical test would be a valuable
tool for surgeons to identify the TKR patients who are
speciﬁcally at a risk of venous thromboembolic events.
During the conversion of prothrombin to thrombin,
the prothrombin fragment 1+2 (F1+2, molecular weight
∼31,000D [2]) is formed as a by-product [3]. Therefore,
the coagulation status can be determined by measuring
F1+2 levels in plasma [4, 5]. Due to its molecular size,
F1+2 is excreted in urine (uF1+2). It has previously been
reported that measurements of uF1+2 by an enzyme-
linked immunosorbent assay (ELISA) can be used to iden-
tify patients at risk for symptomatic and asymptomatic
VTE and symptomatic arterial vascular events after THR
[6, 7]. Furthermore, in patients who experienced bleeding
complications after THR, a signiﬁcantly less pronounced
coagulation response with low median uF1+2 levels was seen
in the postoperative period compared with sex- and age-
matched control patients and THR patients with venous
thromboembolic events [7].
The present study was performed to assess whether
measurements of uF1+2 would also be useful in patients
undergoing TKR to diﬀerentiate between patients who are
at risk for VTE or bleeding. This study showed that patients
withVTEtendtohavesigniﬁcantlyhigheruF1+2levelswhen
compared with patients without events between days 1 and 7
after TKR surgery.2 Thrombosis
Table 1: Baseline characteristics of the cases and the sex- and age-matched, event-free control group. ∗Creatinine clearance for men:
(140 − age) × weight / (72 × serum creatinine, mg/dL); creatinine clearance for women: 0.85 × (140 − age) × weight / (72 × serum
creatinine, mg/dL).†n = 138. ‡n = 137.
Venous thromboembolic event
patients (n = 142)
Control patients (n = 140)
Males/females, n (%) 50/92 (35.2/64.8) 50/90 (35.7/64.3)
Age, years, median (range) 70 (48–85) 69 (48–86)
Height, cm, median (range) 165.1 (142–195.6) 165.0 (140–193)
Weight, kg, median (range) 86.3 (52–124.9) 84.1 (53.3–140.9)
Body mass index, kg/m2, median (range) 30.3 (20.8–48.4) 31.0 (19.7–49.5)
Creatinine clearance, mL/min; calculated, median (range)∗ 92.4 (34.9–224.7)† 88.6 (32.0–184.0)‡
2. Methods
2.1. Study Design. This study was conducted in parallel with
a phase II investigation of rivaroxaban for the prevention
of VTE in patients undergoing primary elective TKR [8].
Detailedinclusionandexclusioncriteriahavebeenpublished
previously [8]. Patients received oral rivaroxaban (2.5, 5, 10,
20,or30mgtwicedaily)orsubcutaneousenoxaparin(30mg
twice daily) for 5–9 days. Continued thromboprophylaxis
after completion of the study period was at the discretion of
the investigators. The local ethics committees approved the
study, and all patients provided written, informed consent
before participation. Mandatory bilateral venography was
performed 5–9 days after the operation, most commonly
on days 6 (28/142), 7 (57/142), or 8 (36/142). The local
radiologists initially assessed the venograms, and an expert
adjudication committee subsequently performed a central
assessment. Only the results of the central assessments are
used in this study. Diagnoses of symptomatic VTE, deep
vein thrombosis (DVT), or pulmonary embolism (PE) were
conﬁrmed by objective testing.
2.2. Patients and Controls. All patients with a venous
thromboembolic event, symptomatic or non-symptomatic,
were included in the present study. Age- and sex-matched
controls, without events either at the local or at the central
reading or other vascular events/death, were randomly
selectedwithoutknowledgeoftheiruF1+2results.Inthecase
of deaths where vascular involvement could not be ruled out,
urine samples were also analysed.
2.3. Laboratory Analyses and Urine Sampling. Spot urine
samples were collected from patients in the morning before
TKR surgery, on days 1 and 3 after surgery, on the day of
venography(betweenday5and9)andatfollow-up(day 39).
The samples were snap-frozen and stored at −80◦C until
batchwise analysis after completion of the main study. The
analyses were performed by a laboratory technician blinded
to the clinical course of the individual patients. Levels of
uF1+2 were measured using a commercially available ELISA
kit (Enzygnost F1+2, monoclonal, Dade Behring, Marburg,
Germany) on a BEP 2000 analyser (Dade Behring, Marburg,
Germany). The previously reported cut-oﬀ level of uF1+2
between 0.3 and 0.5nmol/L for symptomatic VTE events [6]
was based on analyses with another ELISA kit (micro) from
the same manufacturer. According to information supplied
from the company, the following equation can be used to
convert between the two kits: ELISA 1 (monoclonal) = 0.265
× ELISA 2 (micro)−29.4 in pmol/L. Thus, in this context,
a uF1+2 between 0.3 and 0.5nmol/L is equivalent to uF1+2
between 50 and 103pmol/L with the new kit.
2.4. Statistical Analyses. Matching was done by randomly
selecting one patient from the suitableevent-free controls for
eachoftheVTEpatients.Multiplelogisticregressionanalysis
wasusedtoexplore the relationship between the incidence of
VTE events and uF1+2 levels on the diﬀerent sampling days,
with treatment group as a factor [9–11]. The linear term of
uF1+2 levels was included as a covariate in these models.
The nonparametric Wilcoxon rank sum test was used to
comparethemediansofuF1+2levelsbetweenVTEcasesand
controls on the diﬀerent sampling days. This method was
used because the data were not normally distributed within
cases and controls. The results were considered statistically
signiﬁcant if the two-sided P value was <.05. The statistical
program package SAS (versions 8.2 and 9.1) was used for the
statistical evaluation.
3. Results and Discussion
Three patients with symptomatic events, two with PE
(of which one was fatal on day 41) and one with DVT,
were excluded from the analyses because of missing urine
samples on all of the days of sampling. This study included
142 patients with a VTE event and 140 control cases. Four
patientshadPEand138hadDVT,ofwhichsevenweresymp-
tomatic and the rest were non-symptomatic. Three deaths
occurred, two due to PE and one due to cardiorespiratory
failure. The baseline characteristics of the cases and the
control group were similar (Table 1), and there was an equal
distribution in terms of weight, height, and body mass
index. No diﬀerences in renal function, as indicated by
creatinine clearance, were seen between the two groups. The
distribution of patients according to study medication (type
and dose) and the median uF1+2 levels on any sampling day
are shown in Table 2. In general, the median uF1+2 levels inThrombosis 3
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Table 3: Levels of prothrombin fragment 1+2 excreted in urine in the VTE and the control groups. Values shown are median (lower limit
of detection 20pmol/L, upper limit 1,200pmol/L). ∗Wilcoxon test (two-sided). †D a yo fv e n o g r a p h yw a sd a y7± 2 after surgery. TKR: total
knee replacement; VTE: venous thromboembolism.
Prothrombin fragment 1+2 levels in urine, pmol/L, median (range)
VTE group (n = 142) Control group (n = 140) P value∗
Day of TKR 20 (<20–1,025) 20.7 (<20–457.5) .45
Day 1 after TKR 141.0 (<20–>1,200) 71.8 (<20–>1,200) .0032
Day 3 after TKR 295.9 (<20–>1,200) 130.8 (<20–>1,200) .0002
Day of venography† 39.7 (<20–869.1) 30.0 (<20–660.2) .0083
Follow-up (day 39) 23.0 (<20–>1,200) 20.9 (<20–831.8) .3445
therivaroxabangroupswerehigheronthedayofvenography
intheVTEcasescomparedwiththecontrolswithsubstantial
variation between the diﬀerent dose regimens, but with no
diﬀerencesseenontheotherdays.Logisticregressionmodels
suggested that there were no diﬀerences across the treat-
ment regimens in terms of the uF1+2 levels preoperatively
(P = .51) or on the day of follow-up (day 39) (P = .35).
However, on the day of venography, uF1+2 was positively
associated with the observed VTE event rate (P = .0015),
but there was also a residual eﬀect of rivaroxaban versus
enoxaparin (odds ratio, 0.40; 95% conﬁdence interval,
0.20–0.76; P = .0049). The study was not powered to show
anydose–responsediﬀerencesbetweentherivaroxabandoses
(P = .18). Due to the non-symptomatic nature of the major-
ityoftheVTEeventsandtheirunknownclinicalimportance,
it was decided to compare the uF1+2 levels in VTE cases
and controls by pooling the diﬀerent study medications and
regimens on the respective days of sampling.
Table 3 shows the median uF1+2 levels on the respective
daysofsamplinginVTEcasesandcontrols.TheuF1+2levels
were not statistically diﬀerent in the two groups preopera-
tively and at follow-up (P = .44 and P = .32, respectively);
however, on day 1 and 3 after the operation and on the day
of venography, the median uF1+2 level in the VTE patients
wassigniﬁcantlyhigherthanthemedianlevelinthecontrols.
The day-to-day changes of the median uF1+2 levels observed
areshownschematicallyinFigure 1.ThemedianuF1+2level
increased from the day of surgery reaching a maximum on
day 3 in both cases and controls; it then declined, and at
follow-up it approximated the preoperative level.
There were 11 symptomatic VTE events in patients with
available urine samples on at least one of the sampling days.
Urine samples were missing on the day of venography in
four patients, two with PE and two with symptomatic DVT.
Table 4 shows the uF1+2 levels preoperatively and on the
day of venography (day of urine sampling). In addition, the
day and the type of event are shown. There was a tendency
towards lower uF1+2 levels when there was a time delay
between the day of urine sampling and the day of the event.
The variations seen may be due to diﬀerences in prophylactic
treatment and variations in kidney function. A 71-year-old
woman who possibly had a fatal PE on day 14 (but this
was never established by objective means) and a 53-year-
old woman who developed symptoms of PE on day 23
(her venography was normal on day 8) both had uF1+2
20
100
400
Day 0
1,200
C
o
n
t
r
o
l
s
C
a
s
e
s
C
o
n
t
r
o
l
s
C
a
s
e
s
C
o
n
t
r
o
l
s
C
a
s
e
s
C
o
n
t
r
o
l
s
C
a
s
e
s
C
o
n
t
r
o
l
s
C
a
s
e
s
Day 1 Day 3 Day 7 ± 2 Day 39
F
r
a
g
m
e
n
t
1
+
2
Figure 1: Box-and-whisker plot for the prothrombin fragment
1+2 excreted in urine. Box-and-whisker plot for the prothrombin
fragment 1+2 excreted in urine in the venous thromboembolism
group (Cases) and the matched, event-free, control group on
each sampling day. Prothrombin fragment 1+2 levels (pmol/L)
are plotted on a logarithmic scale. Day 0 is the day of total knee
replacement. Day 7 ± 2 is the day of venography. Day 39 is the day
of follow-up. Boxes are lower and upper quartiles with the median
represented as the line in the box. The extremes of the whiskers are
the quartiles ± 1.5 times the interquartile range, with outliers given
as points.
<20pmol/Lonthedayofvenography.Therewasnoevidence
of diﬀerences in uF1+2 levels between men and women.
In this study of patients who had undergone TKR,
signiﬁcantly higher uF1+2 levels were observed on day 1 and
3aftertheoperationandonthedayofvenographyinpatients
with VTE events (symptomatic and non-symptomatic)
compared with age- and sex-matched event-free controls.
This indicates that measurement of uF1+2 is also feasible in
this orthopaedic patient category.
It is well known that TKR patients diﬀer from THR
patients in terms of risk of venous thromboembolic events,
type and location of events, and timing of events after
surgery [1]. The incidence of DVT after TKR is higher than
after THR, but with lower rates of proximal thrombi and
symptomatic VTE events, and there is generally an earlier
occurrence of postsurgical symptomatic events [12, 13].Thrombosis 5
Table 4: Results for patients with symptomatic venous thromboembolic events. Patients with symptomatic venous thromboembolic events,
type of event, day of event, day of venography, and levels of prothrombin fragment 1+2 excreted in urine preoperatively and on the day of
venography. Lower limit of detection 20pmol/L, upper limit 1,200pmol/L. CT: computerized tomography; CUS: compression ultrasound;
DVT: deep vein thrombosis; NS: no urine sample; PE: pulmonary embolism; uF1+2: prothrombin fragment 1+2 excreted in urine.
Sex,
M/F
Age,
years
uF1+2
preoperatively,
pmol/L
Day of venography
(day of urine
sampling)
uF1+2 on day of
venography,
pmol/L
Type of
event
Day of
event Comment
F7 1 N S 1 0 <20 PE 14
Bilateral asymptomatic distal DVT. Not
treated. Fatal PE could not be excluded, but
was never objectively conﬁrmed
F5 3 2 7 8 <20 PE 23 Planned venography normal
F6 8 <20 — NS PE 4 PE conﬁrmed by CT
M6 2 <20 — NS PE 8 PE conﬁrmed by CT
M 51 68.1 8 702.5 DVT 8 Distal DVT. Diagnosed by planned venography
F 73 21.5 6 46.5 DVT 7 Distal DVT. Symptoms appeared on the day
after the planned venography
F 55 35.4 5 28.5 DVT 7 Distal DVT. Diagnosed by planned venography
F8 0 <20 7 31.6 DVT 7 Distal DVT. Diagnosed by planned venography
F6 0 <20 — NS DVT 7 Diagnosed by planned venography
F 71 58.7 6 168.2 DVT 16 Proximal DVT. Planned venography
normal. CUS diagnosis on the event day
M 62 54.5 — NS DVT 5 CUS diagnosis venography not performed
These observations could lead to the assumption that the
temporal sequence of activation of coagulation after TKR is
more intense than after THR and has been explained by the
fact that the operative procedure used in knee arthroplasty
involves more bone and soft tissue traumatization than
the procedure used in hip arthroplasty, and thereby results
in more tissue factor release and subsequently in more
pronounced thrombin generation. Some of the observed
uF1+2 levels in the present study seen in both the VTE
patients and the controls seem to support this hypothesis.
Whencomparingobservationsonday3inaparallelandvery
similarstudywithTHRpatients[7],themedianuF1+2levels
in that study were 127.3pmol/L in the VTE patients and
70.6pmol/Linthecontrols.Thiswasconsiderablylowerthan
the levels of 279.6pmol/L and 130.1pmol/L, respectively,
observed on the same day relative to surgery in the present
study. In addition, on the day of venography, the levels
were higher after TKR (39.7pmol/L) than those after THR
(30.8pmol/L) in the VTE patients but at almost the same
level in the controls in the present study (30.5pmol/L) and
in the previous study (30.1pmol/L). It should, however, be
noted that some of the venographies were done one day
earlier in the present study (60% on days 6 and 7) compared
with the THR study (79% on day 7 or later), but this is
unlikely to explain the markedly higher uF1+2 levels in the
VTE patients. These observations could be an indication of
more pronounced coagulation activation after TKR in the
ﬁrst days after surgery.
Unlike in the THR study [7], a signiﬁcantly higher
median uF1+2 level was observed on day 3, but not on
the day of venography in VTE patients compared with the
event-free controls. Signiﬁcantly higher uF1+2 levels were
observed on days 1 and 3 and the day of venography in
the present study, which is also an indication of more
pronounced coagulation in these patients. However, the day-
to-day changes of the median uF1+2 levels are similar during
the time course after TKR, with the maximum elevation seen
on day 3 after surgery (Figure 1). This is similar to results
reported previously in a study of THR patients [6]. Thus
in principle, by using the test described in this paper, it
would be possible to identify which patients need continued
thromboprophylaxis due to continued coagulation activity,
and thus a continued risk of VTE events. In a global
registry study, it was reported that 27% of TKR patients
did not receive prophylaxis 7 days after surgery, although
symptomatic VTE events occurred after discharge in 57% of
the patients [13].
Eleven patients in this study developed a symptomatic
venous thromboembolic event, most ofwhich occurredearly
in the postoperative period. On the day of venography,
uF1+2 levels in some of these patients did not diﬀer from
uF1+2 levels in patients with asymptomatic events. In
addition, the uF1+2 levels in some of these patients did not
even reach the lower end of the previously presented cut-oﬀ
interval of 50pmol/L [7]. An explanation for this could be
that the same cut-oﬀ cannot be applied to THR and TKR
patients. Urine samples from the day of venography were
missing in four patients (36%) in this study. In addition,
there was a substantial time delay between the day of urine
collectionandthedayoftheevent,10to15days,respectively,
in two cases (in one the venography was normal and in
another an objective diagnosis of PE was never established
because the patient died). It was originally planned to have
a urine sample on the day of the event; however, this was6 Thrombosis
not done in any of these cases and, therefore, it is not
readily possible to assess whether the uF1+2 levels changed,
as seen in a previous study after THR [7]. It is, however,
recommended that the test is repeated after surgery at
preset time intervals, always after cessation of prophylaxis
and whenever there is a clinical suspicion of a venous
thromboembolic event. This is very easy to do due to the
non-invasive character of this test principle.
D-dimer (DD) is often used to rule out the presence of
VTE in a patient with clinical symptoms. The diagnostic
capacity of DD in the diagnosis of non-symptomatic DVT
compared with venography has been studied after THR and
TKR. However, the results were disappointing, probably due
to the activating eﬀect of surgery per se, and the test was not
recommended in these patient groups [14, 15].
4. Conclusions
Although the results presented hint at the usefulness of
the measurement of uF1+2 levels, no ﬁrm conclusions
can be drawn as to whether measurement of uF1+2 levels
can be used routinely to assess the presence of VTE after
TKR, except that it seems to be more suited for testing
postoperative patients than DD.
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